Mark Velleca takes over at Black Diamond; Verve Therapeutics separates CMO, CSO posts
→ David M. Epstein is out as CEO of cancer player Black Diamond Therapeutics, which is putting chairman Mark Velleca in charge. This is Velleca’s third CEO post in less than a decade after running G1 Therapeutics (2014-20) and StrideBio (2021-23). Epstein will still be on the board at Black Diamond, a company that hit the scene in 2018 with $20 million from Versant and quickly followed that up with an $85 million Series B in January 2019. Co-founded by Epstein (not to be confused with Seagen’s David R. Epstein) and Elizabeth Buck, Black Diamond made an impressive Nasdaq debut with an IPO that exceeded $200 million in 2020, but layoffs affected 30% of the staff two years later.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.